38 "Pancreas" clinical trials found.
-
NRG-GI011 A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)Phase
Interventional
-
A Randomized Double-Blind Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated KRAS G12D Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
This is a Phase 3 study for people with metastatic pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. To join the study ...
Phase
Interventional
-
A Randomized Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring
CA240-0030 A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants ...Phase
Interventional
-
A Phase 2 Open-label Study of VS-7375 an Oral KRAS G12D (ON/OFF) Inhibitor as Monotherapy and with Cetuximab in Patients with Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
This is a Phase 2, open-label study for adults with metastatic pancreatic cancer that has a KRAS G12D gene mutation. The study is testing an ...
Phase
Interventional
-
A Phase 3 Double-blind Placebo-controlled Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination with mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants with KRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma
This is a Phase 3 study testing a new drug called ASP3082 to see if it works well and is safe when combined with two ...
Phase
Interventional
-
A Phase 3 Randomized Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
This is a Phase 3 study testing how safe and effective a new drug combination is for people with metastatic pancreatic cancer (PDAC) who have ...
Phase
Interventional
-
EXPANDED ACCESS PROGRAM TO TREAT PATIENTS WITH PREVIOUSLY TREATED METASTATIC PANCREATIC ADENOCARCINOMA WITH DARAXONRASIB
This Expanded Access Program (EAP) provides eligible patients with metastatic pancreatic adenocarcinoma (pancreatic cancer that has spread to other parts of the body) access to ...
Phase N/A Interventional
-
A Phase 3 Multicenter Open-label Randomized 2 Arm Study of Adjuvant Daraxonrasib versus Observation Following Curative Intent Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This is a Phase 3 study for patients with Pancreatic Ductal Adenocarcinoma (PDAC) whose cancer has been removed by surgery. The study is randomized and ...
Phase
Interventional
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that ...Phase
Interventional
-
Cystic Fibrosis Patient Registry
The Cystic Fibrosis Patient Registry has served as the primary database for epidemiologic reports published since 1985; a version of the CF Patient Registry began ...Phase
Non-Interventional
